Volume 26, Number 8—August 2020
Research Letter
SARS-CoV-2 Transmission from Presymptomatic Meeting Attendee, Germany
Table
Characteristics of all meeting participants, including face-to-face contact with the index patient, SARS-CoV-2 test results, symptoms and illness severity, isolation measures, and further contacts*
Pt no. | Country of origin | Contact with index patient† | PCR results | Other test results | Age, y/sex | Signs/symptoms | PGA (date)‡ | COVID-19 severity§ | Isolation measures | Family/other contacts |
---|---|---|---|---|---|---|---|---|---|---|
Pt 1 |
Italy |
Index patient |
Feb 22, positive; Mar 9, negative |
NT |
57/M |
Feb 22–Mar 5,
fever, coughing, sneezing, loss of smell and taste. Exanthema developed on day 7 |
5 (Feb 25) |
Moderate |
Feb 23–Mar 9, hospital isolation; Mar 9–23, home isolation |
Family: 50/F tested negative; Feb 23–Mar 6, home isolation. Others: 4 hospital clinical staff members tested positive; 80 other contacts in 14-d home isolation, all tested negative |
Pt 2 |
Spain |
Dinner and taxi |
Feb 27, positive; Mar 13, negative |
NT |
58/F |
Feb 25–Mar 10, slight coughing, fever (for 1 d), GI symptoms, partial loss of smell |
9.5 |
Mild |
Feb 27–Mar 12, hospital isolation; Mar 13–27, home isolation |
Family: Husband (59/M) tested positive Feb 28, asymptomatic; mother (86/F) tested positive Mar 4. Others: clinical staff member (F) tested positive, fever and headache; >10 others in home isolation, tested negative |
Pt 3 |
Denmark |
Neighbor during meeting |
Feb 29, positive |
NT |
49/M |
None |
10 |
Asymptomatic |
Feb 27–Mar 13, home isolation |
Family: 45/F, 19/M, 15/F, all tested negative. Others: 12 contacts tested negative |
Pt 4 |
France |
Dinner |
Feb 27, positive; Mar 8, negative |
NT |
60/M |
Feb 24–26, headache, slight coughing |
8.5 (Feb 25) |
Mild |
Feb 29–Mar 2, hospital isolation; Mar 2–10, home isolation |
Family: 62/F tested negative. Others: 1 contact tested positive |
Pt 5 |
Germany |
Dinner |
Feb 28, positive; Mar 6, negative; Mar 9, negative |
ELISA (Euroimmun): Mar 10, positive for IgA and IgG |
50/M |
Feb 28–Mar 3, slight coughing, slight weakness; no fever |
9.5 (Mar 2) |
Mild |
Feb 27–Mar 9, home isolation (with family) |
Family: 46/F, 12/F, 11/F, 9/F, 9/M. 46/F tested negative Mar 6; ILI developed, tested positive Mar 13; severe headache, limb pain, high fever, and dyspnea thereafter for 5 d. Others: 1 contact tested negative, 1 contact tested positive |
Pt 6 |
Sweden |
Neighbor during meeting |
NT |
ELISA (Euroimmun): Mar 19, positive for IgA and IgG |
40/M |
None |
10 |
Asymptomatic |
Feb 29–Mar 7, hotel room isolation |
Family: 41/F, 10/M, 9/F, all tested negative Mar 2. Others: no others tested |
Pt 7 |
Germany |
No |
Feb 27, positive; Mar 16, negative; Mar 17, negative |
NT |
61/M |
Feb 24–Mar 18, headache, slight coughing, weakness, loss of smell and taste |
6 (Mar 28) |
Moderate |
Feb 27–Mar 12, hospital isolation; Mar 13–, home isolation |
Family: 56/F, 24/F tested negative, home isolation 14 d. Others: 41 contacts in home isolation after contact (14 d); all tested negative |
Pt 8 |
The Netherlands |
No |
Mar 1, 5, 9, positive; Mar 12, negative |
ELISA (Euroimmun): Mar 7, 18, positive for IgA, neg for IgG |
45/M |
Feb 24 (only), ILI symptoms, fatigue. Feb 24–early April, loss of smell |
6 (Feb 24) |
Moderate |
Feb 27–Mar 8, home isolation (with family) |
Family: 43/F, 13/M and 14/M tested positive (home isolation Feb 29–Mar 8); 43/F ILI symptoms (Feb 27–29), 13/M asymptomatic, 14/M ILI symptoms Feb 25 only.
9/F tested negative (home isolation Feb 29–Mar 11); Others: no others tested or in isolation |
Pt 9 |
Germany |
Taxi |
NT |
NT |
59/M |
None |
10 |
Asymptomatic or NA |
Feb 27–Mar 9, home isolation |
Family; no symptoms, NT. Others: no others tested or in isolation |
Pt 10 |
Sweden |
No |
Feb 27, positive |
NT |
49/F |
Feb 24–Mar 10, ILI symptoms, GI symptoms, nausea |
5 (Feb 26) |
Moderate |
Feb 27–Mar 5, hospital isolation; Mar 5–18, home isolation |
Family: 55/M, 19/F; no symptoms, NT. Others: unknown |
Pt 11 |
Germany |
Dinner |
Feb 28, negative |
NT |
36/F |
None |
10 |
NA |
Feb 26–Mar 8, home isolation (with family) |
Family: 38/M tested negative. Others: unknown |
Pt 12 |
Germany |
No |
Feb 27–Mar 8, positive 6 times; Mar 10–12, negative 2 times |
NT |
33/F |
Feb 23–Mar 1, ILI symptoms, headache and limb pain, weakness, sore throat (mild), loss of appetite; loss of smell and taste for 7 more weeks |
3 (Feb 24) |
Moderate |
Feb 26–Mar 10, hospital isolation; Mar 10–12, home isolation |
Family: 33/M tested negative Feb 26/27, Mar 1; home isolation Feb 26–Mar 7. Others: 2 contacts in home isolation until Mar 7; both remained without symptoms, 1 tested negative |
Pt 13 |
Germany |
No |
Feb 27, positive |
NT |
40/M |
Feb 23–Mar 8, ILI symptoms (cough, limb pain; fever (39.5°C) days 1–4, followed by increased temperature days 5–9 |
5 (Feb 24) |
Moderate |
Feb 26–Mar 4, hospital isolation; Mar 4–9, home isolation (with family) |
Family: 42/F, 11/F, both had increased temperature for 1 d (Mar 1); 11/F tested positive Mar 2), negative Mar 6/9; 42/F tested negative (Mar 2); isolation ongoing even after 2nd negative test. Others: unknown |
Pt 14 | Germany | No | Feb 27, positive; Mar 5, negative; Mar 6, negative | NT | 45/F | Feb 23–Mar 6, headache and limb pain, fatigue; no fever | 5 (Feb 27) | Moderate | Feb 27–Mar 7, hospital isolation | Family: 37/F, no symptoms, tested negative (Feb 27–Mar 7). Others: 15 contacts in home isolation; 14/15 no symptoms, 1 contact had symptoms develop and tested positive |
*Last updated on April 20, 2020. All dates are for 2020. GI, gastrointestinal; ILI, influenza-like; NA, not applicable; NT, not tested; PGA, patient global assessment; Pt, participant.
†Face-to-face contact with the index patient (Pt1) lasting >5 min.
‡Severity of COVID-19 symptoms quantified by the patients related to the time with the most severe symptoms from 1–10 (1, close to death; 10, full health).
§Mild, PGA ≥8; moderate, PGA <8 but no hospitalization required.
Page created: May 11, 2020
Page updated: July 19, 2020
Page reviewed: July 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.